Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) Director Raymond E. Cabillot sold 842 shares of Pro-Dex stock in a transaction dated Friday, March 28th. The shares were sold at an average price of $50.00, for a total value of $42,100.00. Following the sale, the director now owns 278,945 shares of the company's stock, valued at approximately $13,947,250. This represents a 0.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Pro-Dex Price Performance
NASDAQ PDEX opened at $51.40 on Wednesday. Pro-Dex, Inc. has a fifty-two week low of $16.84 and a fifty-two week high of $59.60. The stock's 50-day moving average is $40.45 and its two-hundred day moving average is $40.43. The firm has a market cap of $167.62 million, a P/E ratio of 25.57 and a beta of 0.68. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44.
Pro-Dex (NASDAQ:PDEX - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, beating analysts' consensus estimates of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. On average, analysts anticipate that Pro-Dex, Inc. will post 2 earnings per share for the current fiscal year.
Institutional Trading of Pro-Dex
Institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC grew its stake in Pro-Dex by 34.9% in the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier's stock valued at $119,000 after buying an additional 1,028 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Pro-Dex in the fourth quarter valued at about $202,000. Trexquant Investment LP bought a new position in shares of Pro-Dex in the fourth quarter worth about $252,000. Integrated Quantitative Investments LLC acquired a new position in shares of Pro-Dex during the 4th quarter worth about $254,000. Finally, Arrowstreet Capital Limited Partnership bought a new stake in Pro-Dex during the 4th quarter valued at approximately $255,000. 15.28% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Separately, StockNews.com cut shares of Pro-Dex from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th.
Check Out Our Latest Stock Report on Pro-Dex
Pro-Dex Company Profile
(
Get Free Report)
Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
